At what price was the Neuraxis (NRXS) director share grant reported?

The director share grant was reported at a price of $4.63 per Neuraxis common share. This figure represents the stated price for the 21,598-share equity award granted on January 22, 2026, as disclosed in the Form 4 filing.

Neuraxis director granted 21,598 NRXS shares

Neuraxis, INC director granted shares as equity compensation.

Accepted by SEC EDGAR 02/26/2026 - 09:23 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Neuraxis, INC director granted shares as equity compensation. Director Jane Elizabeth Keyser acquired 21,598 shares of Neuraxis common stock on January 22, 2026 at a stated price of $4.63 per share through a grant, not an open-market purchase.

After this award, she directly owns 46,335 common shares. According to the disclosure, these shares were issued as compensation for her services as an independent director, meaning this is a non-cash equity grant rather than a cash investment into the company’s stock.

Insider Trade Summary

Grant/Award: 21,598 shares

Grant/Award 1 txn

Insider Keyser Jane Elizabeth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,598	$4.63	$100K

Holdings After Transaction: Common Stock — 46,335 shares (Direct)

Footnotes (1)

F1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Neuraxis (NRXS) disclose in this Form 4 filing?

Neuraxis disclosed that director Jane Elizabeth Keyser received a grant of 21,598 shares of common stock. The award was issued as compensation for her services as an independent director, rather than through an open-market stock purchase.

How many Neuraxis (NRXS) shares did Jane Elizabeth Keyser acquire?

Jane Elizabeth Keyser acquired 21,598 shares of Neuraxis common stock. The shares were granted on January 22, 2026 as an equity award, rather than bought on the market, and increase her direct holdings in the company.

What is Jane Elizabeth Keyser’s total Neuraxis (NRXS) ownership after the grant?

Following the grant, Jane Elizabeth Keyser directly owns 46,335 shares of Neuraxis common stock. This total reflects her updated holdings after receiving the 21,598-share equity award as compensation for her role as an independent director.

Was the Neuraxis (NRXS) Form 4 transaction a stock purchase or a grant?

The Form 4 transaction was a grant, not an open-market purchase. The filing classifies the code as a grant or award acquisition, with shares issued to Jane Elizabeth Keyser as compensation for her services as an independent director of Neuraxis.

Why did Neuraxis (NRXS) issue shares to Jane Elizabeth Keyser?

Neuraxis issued shares to Jane Elizabeth Keyser as compensation for her services as an independent director. The footnote explains that 21,598 shares of common stock were granted as part of her director compensation, aligning her interests with company shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keyser Jane Elizabeth

(Last)

(First)

(Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL

46032

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/22/2026		A		21,598	A	$4.63⁽¹⁾	46,335	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.

	/s/ Beth Keyser	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR